drugset / Trial / NCT04258488

Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

NCT04258488

Phase 4 Recruiting 1300 enrolled Joon Bum Kim
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the long-term anticoagulation with oral factor Xa inhibitor versus vitamin K antagonist in patients receiving a mechanical aortic valve replacement.

Timeline

Start
2022-02-21
Primary completion
2027-12-31
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 15 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral
Comparator Warfarin Small molecule